Hummingbird Bioscience is a highly innovative biotech company focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics

  • Novel, integrative approaches to tumor biology
    Recognition of the importance of both tumor evolution and evasion of immune response as a key “hallmark of cancer” has provided a wide new class of targets. Building on these insights, Hummingbird is developing a comprehensive framework to systematically address the barriers to an effective immune response in every patient. 
  • Rational Antibody Discovery Platform
    A highly innovative systems immunology and computational structural biology approach that enables precise targeting of epitopes and mechanism of action
  • Data and model driven translational medicine and biomarker identification
    Mechanism driven -omics analysis informs selection of appropriate pre-clinical models, role of tumor heterogeneity and down-stream biomarker development 

Using these approaches, Hummingbird Bioscience has developed a pipeline of highly promising oncology and immuno-oncology assets, and has established discovery collaborations with leading partners.

Recent News

  • 10 April 2018 Hummingbird Bioscience to present data on HMBD-002-V4 at the American Association for Cancer Research (AACR) 2018 Meeting (Full Press Release)
  • 25 February 2018 Hummingbird Bioscience is featured on Biotech Strategy Blog discussing its CD47 bispecific pipeline (Full Press Release)

  • 4 December 2017 Hummingbird Bioscience to present data on HMBD-004A at the 59th American Society of Hematology (ASH) Annual Meeting (Full Press Release)

  • 3 May 2017 Hummingbird Bioscience announces it has closed a venture funding round of an undisclosed amount from Decheng Capital (Full Press Release)
  • 3 Apr 2017 Hummingbird Bioscience presents latest progress on HMBD-001 and HMBD-002 at AACR in Washington DC
  • 19 Jan 2017 Hummingbird Bioscience awarded SPRING Singapore TECS Grant to support continued development of Rational Antibody Discovery Platform